Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre

Background: Metastatic renal cell carcinoma is chemoresistant and radioresistant disease with poor survival historically, but outcome has improved in past decade after introduction of tyrosine kinase inhibitors like sunitinib and sorafenib. Sorafenib has not been tested in Indian patients with metas...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Hematol Oncol Stem Cell Res
Main Authors: Saxena, Mohith, Madabhavi, Irappa, Patel, Apurva, Panchal, Harsha, Anand, Asha
Format: Artigo
Jezik:Inglês
Izdano: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2018
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6305272/
https://ncbi.nlm.nih.gov/pubmed/30595822
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki